Literature DB >> 18551412

Mutational analysis of genes p14ARF, p15INK4b, p16INK4a, and PTEN in human nervous system tumors.

L O Almeida1, A C Custódio, J J Araújo, J A Rey, J R W Almeida, M J Santos, C A Clara, C Casartelli.   

Abstract

Cancer is one of the most common and severe problems in clinical medicine, and nervous system tumors represent about 2% of the types of cancer. The central role of the nervous system in the maintenance of vital activities and the functional consequences of the loss of neurons can explain how severe brain cancers are. The cell cycle is a highly complex process, with a wide number of regulatory proteins involved, and such proteins can suffer alterations that transform normal cells into malignant ones. The INK4 family members (CDK inhibitors) are the cell cycle regulators that block the progression of the cycle through the R point, causing an arrest in G1 stage. The p14ARF (alternative reading frame) gene is a tumor suppressor that inhibits p53 degradation during the progression of the cell cycle. The PTEN gene is related to the induction of growth suppression through cell cycle arrest, to apoptosis and to the inhibition of cell adhesion and migration. The purpose of the present study was to assess the mutational state of the genes p14ARF, p15INK4b, p16INK4a, and PTEN in 64 human nervous system tumor samples. Homozygous deletions were found in exon 2 of the p15INK4b gene and exon 3 of the p16INK4a gene in two schwannomas. Three samples showed a guanine deletion (63 codon) which led to a loss of heterozygosity in the p15 gene, and no alterations could be seen in the PTEN gene. Although the group of patients was heterogeneous, our results are in accordance with other different studies that indicate that homozygous deletion and loss of heterozygosity in the INK4 family members are frequently observed in nervous system tumors.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18551412     DOI: 10.4238/vol7-2gmr445

Source DB:  PubMed          Journal:  Genet Mol Res        ISSN: 1676-5680


  4 in total

1.  Comparison of the inhibitory effects of three transcriptional variants of CDKN2A in human lung cancer cell line A549.

Authors:  Wei Zhang; Jing Zhu; Jing Bai; Hui Jiang; Fangli Liu; An Liu; Peng Liu; Guohua Ji; Rongwei Guan; Donglin Sun; Wei Ji; Yang Yu; Yan Jin; Xiangning Meng; Songbin Fu
Journal:  J Exp Clin Cancer Res       Date:  2010-06-17

2.  Long non-coding RNA SNHG15 inhibits P15 and KLF2 expression to promote pancreatic cancer proliferation through EZH2-mediated H3K27me3.

Authors:  Zhonghua Ma; Hesuyuan Huang; Jirong Wang; Yan Zhou; Fuxing Pu; Qinghong Zhao; Peng Peng; Bingqing Hui; Hao Ji; Keming Wang
Journal:  Oncotarget       Date:  2017-08-18

3.  Screening of potential novel candidate genes in schwannomatosis patients.

Authors:  Cristina Perez-Becerril; Andrew J Wallace; Helene Schlecht; Naomi L Bowers; Philip T Smith; Carolyn Gokhale; Helen Eaton; Chris Charlton; Rachel Robinson; Ruth S Charlton; D Gareth Evans; Miriam J Smith
Journal:  Hum Mutat       Date:  2022-06-27       Impact factor: 4.700

4.  Nuclear receptor NR5A2 controls neural stem cell fate decisions during development.

Authors:  Athanasios Stergiopoulos; Panagiotis K Politis
Journal:  Nat Commun       Date:  2016-07-22       Impact factor: 14.919

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.